Navigation Links
CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
Date:8/19/2007

as Multikine produced in the same manufacturing facility for Phase III clinical trials and the sale of the product because this arrangement helps to ensure that the drug lots used to conduct the clinical trials will be consistent with those that will be marketed subsequent to approval.

Although some biotech companies outsource their manufacturing, this can be risky with biologics because they require intense manufacturing and process control. With biologic products a minor change in manufacturing and process control can result in a major change in the final product. Good and consistent manufacturing and process control is critical and is best assured if the product is manufactured and controlled in the manufacturer's own facility by their own specially trained personnel. In fact, there have been many situations in which companies had to repeat their Phase III trials or perform an additional clinical bridging study to address regulatory concerns resulting from outsourced manufacturing. This has led to enormous costs and lengthy delays in getting biotech drugs to market. In addition, using a contract manufacturer ties the company's approval to the manufacturing facility of the contractor, further reducing the level of control by the company.

Geert Kersten, Chief Executive Officer of CEL-SCI said, "Manufacturing biologics is such an expensive endeavor that most biotech companies partner with larger companies, and in the process give up their marketing rights. The funding with BioRealty, Inc. will allow us to keep the marketing rights, thereby giving our shareholders the greatest value creation. Now that the significant hurdle of manufacturing has been tackled, we are able to focus on getting Multikine through Phase III, and ultimately to patients."

Stan Wendzel, Managing Director of BioRealty, Inc. said, "After having completed the due diligence on both CEL-SCI and its Multikine product, we recognized that CEL-SCI may fundamentally change the standard
'/>"/>

SOURCE CEL-SCI Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. CEL-SCIS CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals
2. CEL-SCI Presents Long-Term Cancer Survival Data With Multikine
3. CEL-SCIs Cel-1000 Shown to Significantly Enhance Immune Response Against Hepatitis B Antigen in Animals
4. Largest National U.S. Healthcare Facility MRSA Study Reveals Infection Rates Eight Times Greater Than Previous Estimates
5. Vastox Awarded £400,000 Grant to Support R&D at Carbohydrate Chemistry Facility
6. FDA Re-Inspection Results in Positive Re-Classification of Guayama Facility
7. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
8. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
9. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... -- Reportlinker.com announces that a new market research ... Global Patient Scales Industry ... worldwide markets for Patient Scales in US$ Thousand ... & Baby Scales, Chair Scales, and Under Bed ... the US, Canada, Japan, Europe, Asia-Pacific, Latin America, ...
(Date:8/20/2014)... Phase I Trial of Plasma ... KalVista Pharmaceuticals ("KalVista"), an ophthalmology company with a ... it has begun a Phase I, First in Human, ... the treatment of DME. The study,s Principal Investigator is ... Joslin Diabetes Center; Harvard Medical School Department of Ophthalmology, ...
(Date:8/19/2014)... , Aug. 19, 2014  Northwest Biotherapeutics (NASDAQ: ... developing DCVax® personalized immune therapies for solid tumor cancers, ... announced last Thursday, August 14, 2014, has closed.  The ... convertible at $7.30 per share of common stock.  The ... to purchase up to an additional 30% of these ...
Breaking Medicine Technology:Global Patient Scales Industry 2Global Patient Scales Industry 3Global Patient Scales Industry 4Global Patient Scales Industry 5Global Patient Scales Industry 6Global Patient Scales Industry 7Global Patient Scales Industry 8Global Patient Scales Industry 9Global Patient Scales Industry 10Global Patient Scales Industry 11Global Patient Scales Industry 12Global Patient Scales Industry 13Global Patient Scales Industry 14Global Patient Scales Industry 15Global Patient Scales Industry 16Global Patient Scales Industry 17Global Patient Scales Industry 18Global Patient Scales Industry 19KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 2NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 3
(Date:8/20/2014)... 20, 2014 In its latest blog post, ... treatment program that gets clients off to a great start ... believe in, is highlighting an important and possibly life-changing – ... everyone who wants to understand the insidious nature of drug ... belief that drug abuse targets a certain socioeconomic group, such ...
(Date:8/20/2014)... Texas Medical Research Associates is looking for ... help test the effectiveness of a new drug looking to ... be eligible to participate in the study. , According to ... can lead to cardiovascular disease, the no. 1 cause of ... the risk of heart disease and stroke. People with high ...
(Date:8/20/2014)... sleep may wake up to worse consequences than nodding ... of being obese by age 21 was 20 percent ... of sleep a night, compared with their peers who ... Control and Prevention recommends nine to ten hours of ... of Public Health at Columbia University and the University ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 According to ... on August 7 in the multicounty litigation (MCL) case ... RE DEPUY ASR HIP IMPLANTS LITIGATION; no. BER-L-3971-11), nearly ... have been dismissed without prejudice. The cases enumerated in ... of being resolved.” The Rottenstein Law Group LLP, a ...
(Date:8/20/2014)... BCC Research ( http://www.bccresearch.com ) ... AND DETECTORS: TECHNOLOGIES AND GLOBAL MARKETS , the ... to grow to $15.2 billion by 2019, with ... 15.9%. Increasing industrialization is driving significant growth ... expanding range of industrial applications such as military ...
Breaking Medicine News(10 mins):Health News:New A Forever Recovery Blog Post Reminds People that Drug Abuse Doesn’t Discriminate 2Health News:New A Forever Recovery Blog Post Reminds People that Drug Abuse Doesn’t Discriminate 3Health News:Texas Medical Research Associates Announce New Study 2Health News:Teen sleeplessness piles on risk for obesity 2Health News:350 NJ DePuy ASR Lawsuits Dismissed Pending Settlement Talks, Notes Rottenstein Law Group LLP 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 3
... The American Journal of Gastroenterology suggests that smoking may ... in those// who suffer from Crohn’s disease. Where the ... eventually require surgical treatment. ,“In patients who ... the small intestine, rather than the colon,” says study ...
... cold may cause uncommon ailments if neglected, specialists warn. // ... have always thought it is harmless. But specialists say it ... also negatively impact vision or cause harm to any part ... cases of chronic sinusitis because of unchecked pollution. Chronic sinus ...
... has been recommended for medical conditions such as endometriosis, ... choice for women who dislike menstruation or find it ... and is it a reasonable lifestyle choice, asks Paula ... ,Birth control options that reduce or eliminate periods ...
... new cancer research study that may be the ‘last best ... to discover the genetic and environmental factors that cause and ... aims to enroll a geographically and ethnically diverse group of ... pave the way for the next generation of American Cancer ...
... the counter (OTC) drugs can be highly addictive, warn two ... of dependency on OTC drugs is often forgotten, write Drs ... months, they describe seeing three patients with addictions to Nurofen ... started using the product for its approved indications, but their ...
... benefit from having a tonsillectomy in the short term, ... and any benefits have to be balanced against the ... small study of adults from Finland showed that tonsillectomy ... days, compared with watchful waiting. ,But despite ...
Cached Medicine News:Health News:A Cold Shoulder to Cold - At Your Risk 2Health News:Should Menstrual Suppression Be a Lifestyle Choice? 2Health News:American Cancer Society Launches Major New Study 2Health News:American Cancer Society Launches Major New Study 3Health News:Is It Worth Having Surgery to Remove Your Tonsils? 2
... contamination, which causes false ... Hydrophobic, nonwicking and self-sealing ... pass through these aerosol-resistant ... to tips with absorption ...
Inquire...
... Finntip Filters are ideal ... methods, or for any work ... They are designed for pipetting ... samples, and other. For applications ...
... Finntip Filters are ideal for ... or for any work where ... are designed for pipetting DNA/RNA ... and other. For applications requiring ...
Medicine Products: